Ad hoc announcement pursuant to Art. 53 LR

Samuel Künzli succeeds Niklaus Ramseier as CFO and member of the Executive Board

Burgdorf, 29.09.2023, 7:00 a.m. – Ypsomed (SIX: YPSN) announces a change in its Executive Board. After more than twenty years, Niklaus Ramseier will hand over his functions as Chief Financial Officer (CFO) on 31 March 2024 and will continue to be available to the company for strategic projects. His successor is Samuel Künzli, who will start his position as CFO on 01 April 2024.

Niklaus Ramseier has been CFO at Ypsomed (formerly Disetronic) since 2002. Since then, he has headed the Finance & Controlling department. He was also in charge of the IT department until mid-2022. At the end of March 2024, he will hand over his functions as CFO and member of the Executive Board and will continue to be available to Ypsomed on a reduced basis for strategic projects until his early retirement in January 2025.

„Niklaus Ramseier has accompanied our company for more than two decades with a lot of expertise and great commitment as CFO. Thanks to his competence and reliability, we were able to master numerous challenges in the past and successfully prepare the company for the continued growth phase. We thank Niklaus Ramseier for his valuable contributions to the company and are pleased that he is available to us for the further transformation. At the same time, I am pleased that we were able to win Samuel Künzli, a proven financial expert with capital market experience, as his successor. I am convinced that Samuel Künzli will optimally support the execution of our strategy. We give him a warm welcome", says CEO Simon Michel, commenting on the upcoming change in the Executive Board.

For the past three years, Samuel Künzli has been CFO and a member of the Group Management at Feintool Group. He previously worked for Stadler for eight years in various financial management roles, most recently as CFO of the Division Switzerland. Samuel Künzli is a Swiss certified accountant and holds a Master's degree in finance and accounting from the University of St. Gallen (HSG), among other qualifications.

Contact
Thomas Kutt, Investor Relations, Ypsomed Holding AG
+41 34 424 35 55, thomas.kutt@ypsomed.com

About Ypsomed
Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 35 years of experience. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brands mylife Diabetescare directly to patients or via pharmacies and hospitals as well as under YDS Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. The company is headquartered in Burgdorf, Switzerland, and has a global network of production facilities, subsidiaries and distribution partners employing a staff of over 2,200 employees worldwide: www.ypsomed.com